Detalhe da pesquisa
1.
Maraviroc, as a Switch Option, in HIV-1-infected Individuals With Stable, Well-controlled HIV Replication and R5-tropic Virus on Their First Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Plus Ritonavir-boosted Protease Inhibitor Regimen: Week 48 Results of the Randomized, Multicenter MARCH Study.
Clin Infect Dis
; 63(1): 122-32, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27048747